Aza–ven combination outperforms standard care in AML patients eligible for intensive chemotherapy

In a new trial, patients newly diagnosed with acute myeloid leukemia (AML) fared significantly better with a combined regimen ...

Black patients with AML are younger at diagnosis, experience poorer survival outcomes than white patients, data show

Compared with white patients, Black patients with acute myeloid leukemia (AML) were on average more than five years younger at diagnosis, more than 30% more likely to die of their disease, and more ...